SCHEMBL298615

SCHEMBL298615

Oc1cccc2cccc(Br)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
MCL1 Q07820 2/20 0.50
DNMT1 P26358 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
CDK2 P24941 3/20 0.47
HPGD P15428 6/20 0.42
HSD17B10 Q99714 6/20 0.42
ALOX15 P16050 5/20 0.42
MAPT P10636 5/20 0.42
RECQL P46063 4/20 0.42
TDP1 Q9NUW8 4/20 0.42
TSHR P16473 4/20 0.42
CYP1A2 P05177 3/20 0.42
SNCA P37840 3/20 0.42
THRB P10828 2/20 0.42
APP P05067 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11772851 0.82 CTDSP1 (0.47) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL29363189 0.81 ALDH1A1 (0.62) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL29374267 0.81 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMCL1CDK2
SCHEMBL1187339 0.81 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMCL1CDK2
SCHEMBL70219 0.81 ALDH1A1 (0.62) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL6544874 0.79 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL5356612 0.79 CDK2 (0.47) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL28357450 0.78 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AMCL1CDK2
SCHEMBL29405571 0.78 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AMCL1CDK2
SCHEMBL7126508 0.78 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AMCL1DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 US disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 US disclosed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 CN disclosed
CN-117865902-A Organic electronic transmission material, light emitting device and display panel 京东方科技集团股份有限公司 2024-04-12 CN disclosed
CN-117660992-A Synthesis method of organosilicon compound containing Si-O bond 新疆大学 2024-03-08 CN disclosed
US-20230389423-A1 HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES UDC IRELAND LIMITED (IE) 2023-11-30 US disclosed
US-20230389423-A1 HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES UDC IRELAND LIMITED (IE) 2023-11-30 US disclosed
CN-114230702-B Olefin polymerization catalyst with naphthoxy skeleton, preparation method and application 万华化学集团股份有限公司 2023-10-13 CN disclosed
US-20230279025-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-09-07 US disclosed
WO-1998017616-A1 PRODUCTION OF NABUMETONE OR PRECURSORS THEREOF ALBEMARLE CORPORATION (US) 1998-04-30 WO disclosed
EP-0416038-B1 NOVEL CHEMILUMINESCENT FUSED POLYCYCLIC RING-CONTAINING 1,2-DIOXETANES AND ASSAYS IN WHICH THEY ARE USED TROPIX INC (US) 1997-03-26 EP disclosed
EP-0416038-A4 NOVEL CHEMILUMINESCENT FUSED POLYCYCLIC RING-CONTAINING 1,2-DIOXETANES AND ASSAYS IN WHICH THEY ARE USED 1992-02-26 EP disclosed
EP-0416038-A1 NOVEL CHEMILUMINESCENT FUSED POLYCYCLIC RING-CONTAINING 1,2-DIOXETANES AND ASSAYS IN WHICH THEY ARE USED. TROPIX INC (US) 1991-03-13 EP disclosed
US-4952707-A DECOMPOSITION TO LIGHT EMITTING FLUOROPHORE; ANALYSIS TROPIX, INC. (US) 1990-08-28 US disclosed
WO-1990000164-A1 NOVEL CHEMILUMINESCENT FUSED POLYCYCLIC RING-CONTAINING 1,2-DIOXETANES AND ASSAYS IN WHICH THEY ARE USED TROPIX, INC. (US) 1990-01-11 WO disclosed
US-4061642-A AZO DYE INTERMEDIATES CASSELLA FARBWERKE MAINKUR AG (DT) 1977-12-06 US disclosed
US-3956294-A AZO DYES, PESTICIDES, ANALEPTICS, ANALGESICS, DIURETICS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-05-11 US disclosed
US-3954782-A 2,6-Hydrazino-3-pyridine carboxyamides CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-05-04 US disclosed
US-3947463-A Certain 2-amino-nicotinonitrile derivatives CASSELLA FARBWERKE MAINKUR AG (DT) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279025-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2943/4885MEN1 456/4885KMT2A 1839/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ALDH1A1 1816/4885MEN1 924/4885KMT2A 2950/4885
US-20230389423-A1 HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES DDT, VDAC2, KCNC1 ALDH1A1 525/4885MEN1 1667/4885KMT2A 2184/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ALDH1A1 1957/4885MEN1 258/4885KMT2A 2336/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2681/4885MEN1 465/4885KMT2A 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.